先聲藥業(02096.HK)抗新冠候選藥物臨床試驗獲批准

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

先聲藥業(02096.HK)抗新冠候選藥物臨床試驗獲批准

阿思達克 05-17 01:24

先聲藥業(02096.HK)公布，集團與中國科學院上海藥物研究所、武漢病毒研究所合作的抗新型冠狀病毒(「SARS-CoV-2」)候選藥物SIM0417已獲得國家藥品監督管理局簽發的藥物臨床試驗批准通知書，擬用於曾暴露於新冠檢測陽性感染者的密接人群的暴露後預防治療。在已完成的臨床前試驗中，SIM0417顯示出廣譜抗病毒活性，良好的體內藥代動力學特性和安全性，是一款高活性、低毒性、可口服的小分子抗SARS-CoV-2候選藥物。

先聲藥業(02096.HK)

Relevant Stocks

先聲藥業(02096.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

先聲藥業(02096.HK)抗新冠候選藥物臨床試驗獲批准

Services

About Us

Agreement Statement